Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

MILLENNIUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1993-01-01

Employees: 1K

Market Cap: -

Website: http://www.takedaoncology.com

Clinical Trials

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Phase 1

Completed

Conditions: Nonhematologic Neoplasms, Advanced

Interventions: Drug: TAK-931

First Posted Date: 2016-03-04

Last Posted Date: 2021-02-21

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 80

Registration Number: NCT02699749

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Phase 1

Completed

Conditions: Neoplasm, Advanced or Metastatic

Interventions: Drug: TAK-117
Drug: Lansoprazole

First Posted Date: 2015-12-09

Last Posted Date: 2018-01-08

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 54

Registration Number: NCT02625259

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Azacitidine
Drug: Pevonedistat

First Posted Date: 2015-11-20

Last Posted Date: 2022-09-19

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 120

Registration Number: NCT02610777

Locations: 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸
Greenville Health System, Little Rock, Arkansas, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 56 locations

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

Phase 1

Terminated

Conditions: Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Interventions: Drug: MLN1117
Drug: Alisertib
Drug: TAK-659
Drug: Paclitaxel
Drug: Docetaxel

First Posted Date: 2015-09-16

Last Posted Date: 2019-09-20

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 32

Registration Number: NCT02551055

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

Phase 1

Completed

Conditions: Non-hematologic Malignancy

Interventions: Drug: Sapanisertib
Drug: Paclitaxel

First Posted Date: 2015-04-09

Last Posted Date: 2020-02-28

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 61

Registration Number: NCT02412722

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: TAK-117

First Posted Date: 2015-03-19

Last Posted Date: 2018-02-07

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 14

Registration Number: NCT02393209

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

Phase 1

Terminated

Conditions: Gastroesophageal Junction Adenocarcinoma
Recurrent Gastrointestinal Carcinoma
Recurrent Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Advanced Gastrointestinal Carcinoma
Metastatic Gastric Adenocarcinoma
Recurrent Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: MLN0264

First Posted Date: 2015-03-18

Last Posted Date: 2017-03-29

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 12

Registration Number: NCT02391038

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors
Ovarian Cancer
Small Cell Lung Cancer

Interventions: Drug: Alisertib
Drug: Paclitaxel

First Posted Date: 2015-02-20

Last Posted Date: 2019-06-26

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 9

Registration Number: NCT02367352

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Phase 1

Completed

Conditions: Advanced Nonhematologic Malignancies

Interventions: Drug: MLN2480
Drug: MLN0128
Drug: Alisertib
Drug: Paclitaxel
Drug: Cetuximab
Drug: Irinotecan

First Posted Date: 2014-12-30

Last Posted Date: 2020-02-25

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 81

Registration Number: NCT02327169

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 11 locations

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Phase 1

Completed

Conditions: Advanced Solid Tumors
Relapsed/Refractory Lymphoma

Interventions: Drug: Alisertib
Drug: Itraconazole

First Posted Date: 2014-10-08

Last Posted Date: 2019-09-20

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT02259010

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy